+ Watch EPRS
on My Watchlist
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
Ok, I was wrong. Stocklasar, charlie17, Fungusface, Monkeynutz and the whole gang schooled me on this stock. Zalicus is certainly destined for greatness. Exalgo revenues are blowing the roof off exactly as predicted, and the Synavive trial is a certain success. Thanks for showing me the light, guys! See you at $50!
Wait a minute..... does something smell in here?
Wait, what? Doesn't this stock still stink?
It actually blows. I was trying to catch a little rebound but underestimated the frailty of the Zalicus longs. It seems they bark harder than they bite.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions